NICE recommends panobinostat
The National Institute for Health and Care Excellence has recommended panobinostat, in combination with bortezomib and dexamethasone, within its marketing authorisation, as an option for treating adult patients with relapsed or refractory multiple myeloma or both who have received at least two prior regimens including bortezomib and an immunomodulatory agent. The company must provide panobinostat with the discount agreed in the patient access scheme.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200584
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com